Evaluating Quality of Life After Radiation Therapy for Liver Cancer
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
This study is trying to see how radiation therapy affects the quality of life for people with liver cancer over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT03253536 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life in patients with hepatocellular carcinoma who undergo stereotactic body radiation therapy (SBRT). Participants will receive standard treatment and follow-up care, with additional quality of life measurements taken at various time points using validated questionnaires. The study will involve imaging techniques and individualized treatment planning based on specific patient factors. The focus is on understanding how SBRT impacts patients' overall well-being over time.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically or radiologically proven hepatocellular carcinoma and 1-3 lesions suitable for SBRT.
Not a fit: Patients under 18, those with prior systemic therapy for HCC, or those with distant metastases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life improvements for patients undergoing SBRT for liver cancer.
How similar studies have performed: While this approach is observational, similar studies evaluating quality of life after radiation therapy have shown promising results, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically or radiologically proven hepatocellular carcinoma * 1-3 lesions suitable for stereotactic radiation therapy * indication for SBRT according to multidisciplinary board evaluation * age \>= 18 years * written informed consent for study participation * mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician) Exclusion Criteria: * age \< 18 years * prior HCC specific systemic therapy * concurrent oncological systemic treatment * distant metastases * inadequate ability tobe compliant with the protocol or to complete standardizes questionaires * inability to receive contrast-enhanced planning CT * missing ability to give informed consent * legal custody
Where this trial is running
Munich, Bavaria
- Department of Radiation Oncology, University Hospital, LMU Munich — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Falk Roeder, MD — Department of Radiation Oncology, University Hospital, LMU Munich
- Study coordinator: Falk Roeder, MD
- Email: Falk.Roeder@med.uni-muenchen.de
- Phone: +49 89 4400 73729
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.